reports
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV A...
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present Phase 3 results from a clinical study comparing efficacy and safety of Humacyte's acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in pa...
AbCellera to Present at Upcoming Investor Conferences in December and ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) Live audio webcasts of the presentation may be accessed through the link that will be posted on . Replays of the webcast will be av...
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Rep...
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery – In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks – – Results were published in a premier peer-reviewed surgical journal sponsored by the American Medical Association – DURHAM, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company develo...
Treace Announces Participation at Stifel 2024 Healthcare Conference
Treace Announces Participation at Stifel 2024 Healthcare Conference PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, beginning at approxi...
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coro...
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024 – sdATEVs maintained sustained patency throughout the six-month study – – sdATEV was observed to recellularize with host cells and remodel to effectively reduce the initial size mismatch between the sdATEV and the animal’s native artery – DURHAM, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commer...
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately $15.0 million worth of its common stock and warrants to purchase common stock in a registered direct offering. Under the terms of the securities purchase agreement, the Company has agree...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nuveen New Jersey Quality Muni Income Fd and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 November 2024 in which we reassessed the appropriateness of the...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Ride the Trend Higher Our outlook remains bullish following the S&P 500's multi-month base breakout above 5670, alongside constructive market dynamics which have significantly improved over the past week. In last week's Compass (11/5/24) titled "Buy the Pullback," we discussed how we were buyers, noting that "once past the election, starting as early as today (election day) or tomorrow (day after the election), we believe there will be a strong end-of-year rally that will extend into the early ...
SF STIFEL FINANCIAL CORP.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MCS MARCUS CORPORATION
EVR EVERCORE INC CLASS A
CCL CARNIVAL CORPORATION
POH3 CARNIVAL PLC
TRUE TRUECAR INC.
CVNA CARVANA CO. CLASS A
PLYA PLAYA HOTELS & RESORTS
CARG CARGURUS CLASS A
JEF JEFFERIES FINANCIAL GROUP INC.
FRHC FREEDOM HOLDING CORP
TNL TRAVEL PLUS LEISURE CO
LAZ LAZARD INC
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Leggett & Platt, Incorporated and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 November 2024 in which we reassessed the appropriateness of the ratings in ...
Norwegian Cruise Line Holdings Ltd: 3 directors
Three Directors at Norwegian Cruise Line Holdings Ltd sold 82,344 shares at between 27.298USD and 27.861USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Humacyte Third Quarter 2024 Financial Results and Business Update
Humacyte Third Quarter 2024 Financial Results and Business Update - FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology’s Kidney Week 2024 - - Long-term results from the humanitarian program where the ATEV was used to treat vascular injuries suffered during the Ukraine conflict were presented at the U.S. Department of Defense’s foremost scientific meeting - - Conferenc...
AbCellera Presents Data on Applications of T-Cell Engager Platform at ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas. AbCellera’s presentation, which is available for viewing , describes: Strategies to address key challenges in TCE development: CD3-binding antibodies to widen the therapeutic window by generating TCEs with potent tumor-cell killing and optimal cytokine release Molecules to enhance efficacy for solid tumor ind...
Humacyte to Present Third Quarter Financial Results and Provide Corpor...
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024 DURHAM, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2024, on Friday, November 8, 2024. Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs. Title:H...
Treace Medical Concepts Reports Third Quarter 2024 Financial Results
Treace Medical Concepts Reports Third Quarter 2024 Financial Results PONTE VEDRA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue of $45.1 million in third quarter 2024 increased 11% over same period in 2023Third quarter 2024 net loss was ($15.4) millio...
Treace Announces Participation in the UBS Global Healthcare Conference
Treace Announces Participation in the UBS Global Healthcare Conference PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at appro...
AbCellera Reports Q3 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant mil...
Treace Comments on CMS’ 2025 Final Rule for Hospital Outpatient and AS...
Treace Comments on CMS’ 2025 Final Rule for Hospital Outpatient and ASC Settings PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today commented on the recently released Centers for Medicare & Medicaid Services (CMS) Calendar Year 2025 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule, effective ...
Treace Enters High Volume Osteotomy Market with Nanoplasty™ 3D Minimal...
Treace Enters High Volume Osteotomy Market with Nanoplasty™ 3D Minimally Invasive Bunion Correction™ Procedure Positions Treace to Significantly Increase Penetration into Overall Bunion Market and Expand Surgeon Customer Base PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced the limited market release of the 3D Minimally Invasive ...
- Brian Violino
- Jay McCanless
Norwegian Cruise Line Holdings Reports Strong Third Quarter 2024 Finan...
Norwegian Cruise Line Holdings Reports Strong Third Quarter 2024 Financial Results Third quarter revenue up ~11% over prior year setting record revenue in a quarter Company beats third quarter guidance across all key metrics and raises full year guidance for fourth time MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd. (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the third quarter ended September 30, 2024 and provided guidance for the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.